1. Home
  2. CALX vs MIRM Comparison

CALX vs MIRM Comparison

Compare CALX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calix Inc

CALX

Calix Inc

HOLD

Current Price

$53.82

Market Cap

4.2B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$69.00

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CALX
MIRM
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.7B
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
CALX
MIRM
Price
$53.82
$69.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$77.75
$82.82
AVG Volume (30 Days)
692.8K
536.5K
Earning Date
10-29-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$933,685,000.00
$471,794,000.00
Revenue This Year
$19.95
$53.14
Revenue Next Year
$12.89
$19.83
P/E Ratio
N/A
N/A
Revenue Growth
4.89
53.66
52 Week Low
$28.61
$36.88
52 Week High
$71.22
$78.55

Technical Indicators

Market Signals
Indicator
CALX
MIRM
Relative Strength Index (RSI) 35.55 44.02
Support Level $53.31 $68.60
Resistance Level $54.81 $71.98
Average True Range (ATR) 1.74 2.55
MACD -0.19 -0.09
Stochastic Oscillator 31.08 7.55

Price Performance

Historical Comparison
CALX
MIRM

About CALX Calix Inc

Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: